PF-Atlas › Clinical Trials › NCT04922554
Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex
Omadacycline Oral Tablet · Phase 2
Registry ID
NCT04922554
Phase
Phase 2
Status
Completed
Drug / intervention
Omadacycline Oral Tablet
Sponsor
Paratek Pharmaceuticals Inc
Start
2021-10-15
About this trial
Omadacycline Oral Tablet is evaluated in NCT04922554, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Paratek Pharmaceuticals Inc. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04922554 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.